Cover Image
市場調查報告書

似胰島素生長因子II:開發中產品分析

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 408077
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
似胰島素生長因子II:開發中產品分析 Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 51 Pages
簡介

本報告提供以似胰島素生長因子II的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

似胰島素生長因子II 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Boehringer Ingelheim GmbH
  • MedImmune LLC

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1306TDB

Summary:

According to the recently published report 'Insulin Like Growth Factor I - Pipeline Review, H1 2018'; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 8 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin.

It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.

The report 'Insulin Like Growth Factor I - Pipeline Review, H1 2018' outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Cardiovascular which include indications Acute Ischemic Stroke, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
  • The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview
    • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim GmbH
    • Genervon Biopharmaceuticals LLC
    • Regulaxis SAS
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles
    • CIGB-845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-610.27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-630 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-7085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit IGF1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xentuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products
  • Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
      • Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
      • Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
      • Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways
      • Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
      • May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
      • May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe
      • Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
      • Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
      • Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
      • Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
      • Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
      • Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
      • Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
      • Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Pipeline by Genervon Biopharmaceuticals LLC, H1 2018
  • Pipeline by Regulaxis SAS, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top